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Anlotinib, as the new RTK inhibitor molecule, has gained significant interest among researchers in drug development 
targeting tumors. In this study, we investigated the efficacy and safety of anlotinib in patients with advanced colorectal 
cancer and analyzed the prognostic factors. A total of 116 patients with advanced colorectal cancer who were treated in the 
oncology center of our hospital from March 2018 to March 2019 were selected. All patients were divided into a control 
group and an observation group according to the random number table method, with 58 cases in each group. The patients in 
the group were given docetaxel treatment, and the observer patients were given anlotinib treatment on this basis. The short-
term efficacy, disease control rate, tumor progression time, median survival time and 1-year survival rate of the two groups 
after treatment were compared; The incidence of adverse reactions during treatment in the two groups; Kaplan-Meier 
method was used to analyze the prognostic factors of colorectal cancer patients. The total effective rate of patients in the 
observation group after treatment with anlotinib in the near future was 44.83%, which was significantly higher than 25.86% 
in the control group, the difference was statistically significant. The disease control rate and 1-year survival rate of the 
observation group after treatment with anlotinib were significantly higher than the control group, the difference was 
statistically significant, and the tumor progression time and survival time of the observation group were significantly longer 
than the control group. There was no significant difference in the total incidence of adverse reactions such as diarrhea, 
nausea and vomiting, leukopenia, thrombocytopenia, oral mucositis between the two groups of patients during treatment. 
Kaplan-Meier method analysis found that age, treatment plan, lymph node metastasis, and residual tumor diameter are all 
risk factors affecting the prognosis of colorectal cancer patients. 
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Colorectal cancer is one of the most common 
malignant tumors in the digestive system. According 
to GLOBACON 2020 report, colorectal cancer is 
rated as 3
rd
 most common cancer affecting humans 
after breast and lung cancer. Incidence of colorectal 
cancer is estimated to be 10% of total 19.3 million 
cases of all types. It accounts for 9.4% of total 10 
million cancer deaths reported worldwide
1
. The rate 
of incidence of colorectal cancer has attracted many 
researchers to work on its pathology, developing 




The onset of colorectal cancer is closely related to 
lifestyle, genetics, and colorectal adenoma. The 
patient has no obvious symptoms in the early stage. 
As the cancer develops, it can show changes in stool 
habits and abdominal pain, blood in the stool, with or 
without systemic symptoms such as anemia and fever, 
threatens the safety of human life
6
. In recent years, the 
incidence of colorectal cancer in China has increased, 
ranking third in the incidence of malignant tumors, 
and its early detection rate is slow. It is prone to 
metastasis. Radiotherapy and chemotherapy can cause 
a variety of toxic and side effects such as hair loss and 
gastrointestinal side reactions, making the patients 
less tolerant to treatment
7,8
. Targeted therapy has 
become a new direction for cancer therapy. Molecular 
targeted therapy refers to the interference of signal 
transduction pathways between cells in the process of 
tumor development. These drugs have the 
characteristics of targeting and non-cytotoxicity, and 
have been studied It was confirmed that molecular 











Anlotinib is a self-developed multi-target 
molecular drug
10
. It is a new type of highly selective 
oral small molecule tyrosine kinase inhibitor. It has 
anti-tumor angiogenesis and tumor growth inhibitory 
effects. Anlotinib can significantly inhibit the growth 
of liver cancer, colorectal cancer, and lung cancer 
mouse tumors and reduce the area of tumor spread
11
. 
In this study, we analyzed the efficacy and safety of 
anlotinib in patients with advanced colorectal cancer 
and also observed the prognostic factors. 
 
Materials and methods 
 
Object source 
A total of 116 patients with advanced colorectal 
cancer who were treated in the oncology center of our 
hospital from March 2018 to March 2019 were 
selected as the research object. This study was 
approved by the hospital ethics committee and 
necessary informed consent was obtained priorly. 
Inclusion criteria:
 
 (i) All patients meet the clinical 
diagnostic criteria for colorectal cancer; (ii) 
Diagnosed as colorectal cancer by pathological biopsy 
or impactology examination; (iii) According to the 
International Anti-Cancer Union TNM stage are all 
stage IV; (iv) Patients with intolerable chemotherapy 
regimen; (v) Age ≥17 years old, expected survival 
time >3 months; and (vi) Patients and family 
members know and cooperate with treatment. 
Exclusion criteria:(i) Critically ill, Carn's score <50; 
(ii) Combined with respiratory failure and severe 
organic diseases; (iii)
 
 Estimated survival time <3 
months; (iv) Those who have participated in other 
anti-tumor drug clinical studies within one month; (v) 
Patients with obvious mental disorders; and (vi) 
Patients with poor treatment compliance caused by 
various reasons are excluded. All patients were 
randomly divided into a control group and an 
observation group, with 58 cases in each group, 
including 36 males and 22 females in the observation 
group, aged 6-18 years, with an average age of 
(6.40±8.5) years, and a disease course of 0.4-3.0 
years, with an average (1.45±0.29) years, including 15 
cases of well-differentiated adenocarcinoma, 18 cases 
of moderately-differentiated adenocarcinoma, 11 
cases of poorly differentiated adenocarcinoma, 14 
cases of mucinous adenocarcinoma; 25 cases of liver 
metastasis, 16 cases of lung metastasis, and 17 cases 
of pelvic abdominal metastasis. In the control group, 
there were 34 males and 24 females, aged 7-18 years, 
with an average age of (5.28±10.54) years, with a 
disease duration of 0.4-3.0 years, with an average 
(1.50±0.31) years, including 16 cases of well-
differentiated adenocarcinoma and moderately 
differentiated adenocarcinoma 32 cases, six cases of 
poorly differentiated adenocarcinoma, four cases of 
mucinous adenocarcinoma; 29 cases of liver 
metastases, 13 cases of lung metastases, 16 cases of 
pelvic and abdominal metastases. After statistical 
testing, the general data of the two groups were 
comparable (P >0.05). 
 
Treatment method 
Patients in the control group were given cisplatin 
for treatment: given docetaxel (specification 20 mg/ 
branch, Jiangsu Hengrui Pharmaceutical Co., Ltd., 
production lot number 160721) 75 mg/m
2
, adding  
250 mL of 0.9% sodium chloride solution, 
intravenous infusion for one hour, each Period 21 d, 
until the patient's disease progression or intolerance of 
adverse reactions, the drug was discontinued. Patients 
in the observation group were given oral anrotinib 
hydrochloride capsules (specification: 12 mg/capsule, 
Zhengda Tianqing Pharmaceutical Group Co., Ltd., 
production batch number: 180204) on the basis of the 
control group, 12 mg, orally before breakfast, once a 
day, continuous medication Withdrawal for two 
weeks for one week, every three weeks is a course of 
treatment, four consecutive courses of treatment. 
During treatment, the two groups should pay attention 
to diet, fasting spicy and stimulating food, and 
strengthen psychological care. 
 
Observation index 
(i) Clinical efficacy: Complete remission: All 
measurable tumor lesions completely disappeared and 
maintained for more than one month; Partial 
remission: The sum of the largest vertical and 
horizontal diameter products of tumor lesions was 
reduced by 50% and maintained for more than one 
month; Stable: Tumor area was reduced by less than 
50% Or increase no more than 25%; Progress: At 
least one lesion increased more than 25% or new 
lesions appeared. Objective effective rate = (complete 
remission + partial remission) / total number of cases 
× 100%, disease control rate = (complete remission + 
partial remission + stable) / total number of cases × 
100%. (ii) Follow-up was conducted by outpatient 
service or telephone call. The cut-off time was March 
2018 or death occurred. The tumor progression time, 
median survival time and 1-year survival rate of the 
two groups were compared. (iii) Observe the 




occurrence of adverse reactions during treatment in 
both groups, including fatigue, nausea and vomiting, 
leukopenia, thrombocytopenia, and oral mucositis. 
 
Statistical analysis 
The measurement data in this study are represented 
by (x±s), the comparison between the observation 
group and the control group by t test, all the count 
data are represented by [n (%)], the comparison of the 
data between the two groups by χ² test, Kaplan-Meier 
method analysis Factors affecting the prognosis of 
patients with colorectal cancer, The value of P <0.05 
was considered statistically significant, and the data 





Comparison of the short-term efficacy of the two groups of 
patients after treatment 
The total effective rate of the observation group 
after anlotinib treatment was 44.83%, which was 
significantly higher than that of the control group, 
25.86%. The difference was statistically significant  
(P <0.05). These results are shown in Table 1. 
 
Comparison of long-term efficacy of two groups of patients 
after treatment 
The disease control rate and 1-year survival rate of 
the observation group after treatment with anlotinib 
were significantly higher than the control group,  
the difference was statistically significant (P <0.05). 
And the tumor progression time and survival time  
of the observation group were significantly longer 
than the control group (P <0.05). These results are 
shown in Table 2. 
 
Comparison of the incidence of adverse reactions between the 
two groups 
There was no significant difference in the total 
incidence of adverse reactions between the two 
groups of patients during the treatment, such as 
fatigue, nausea and vomiting, leukopenia, 
thrombocytopenia, oral mucositis (P >0.05). These 
results are shown in Table 3. 
Table 1 — Comparison of short term efficacy of Control and 
Observation groups of patients after treatment [n (%)] 
Efficacy Control Observation 
Partial relief 14 (24.14) 25 (43.10) 
Stable 17 (29.31) 18 (31.03) 
Improvement 27 (46.55) 15 (25.86) 
Efficient 14 (24.14) 25 (43.10) 
[χ²= 4.674; and P= 0.031. Each group had 58 cases No group had 
complete relief] 
 
Analysis of factors affecting prognosis of patients with 
colorectal cancer 
Kaplan-Meier method analysis found that age, 
treatment plan, lymph node metastasis, and residual 
tumor diameter are all risk factors affecting the 
prognosis of colorectal cancer patients (P<0.05). 
These results are shown in Table 4. 
 
Discussion 
Colorectal cancer is more common in the elderly, 
the patients are more prolonged, and there are no 
obvious symptoms in the early stage, and most of 
them are in the advanced stage. However, occurrence 
among children and young adults cannot be ruled out. 
At present, the main methods of clinical treatment of 
lung cancer include surgery, radiation therapy, 
chemotherapy, traditional Chinese medicine 
treatment, etc. Since more than 50% of patients are in 
advanced stages at the time of treatment, the lesions 
gradually spread to the body and it is not suitable for 
surgical treatment. Patients will still relapse and 
metastasize after receiving treatment. Remote 
Table 2 — Comparison of long-term efficacy of two groups 
(Control and Observation) of patients after treatment (x±s) 
Parameters Control Observation χ² P 
Disease control rate (%) 37 (63.79) 48 (82.76) 5.375 0.020 
1-year survival rate (%) 4 (6.90) 18 (31.03) 10.994 <0.001 












[Each group had 58 cases] 
 
Table 3 — Comparison of the incidence of adverse reactions 
between the two groups [n (%)] 
Adverse reactions Control group Observation group 
Fatigue 2 (3.45) 2 (3.45) 
Feel sick and vomit 1 (1.72) 3 (5.17) 
Leukopenia 1 (1.72) 2 (3.45) 
Thrombocytopenia 1 (1.72) 2 (3.45) 
Oral mucositis 2 (3.45) 3 (5.17) 
Total incidence 7 (12.07) 12 (24.14) 
[χ²= 2.849; and P= 0.091. Each group had 58 cases] 
 
Table 4 — Analysis of factors affecting the prognosis of 










17 year 59 41 (69.49) 4.991 0.025 
≥18 year 57 28 (49.12)   
Treatment 
programs 
Observed 58 40 (68.97) 4.328 0.037 
Control group 58 29 (50.00)   
Lymph node 
metastasis 
Yes 34 6 (17.65) 34.929 <0.001 
No 82 63 (76.83)   
Residual tumor 
diameter 
≤2cm 94 65 (69.15) 19.215 <0.001 
>2cm 22 4 (18.18)   
 




metastasis is the main cause of death in colorectal 
cancer patients
12,13
. Relevant data show that the 5-year 
survival rate of patients with colorectal cancer after 
early radical resection can be as high as 90%, and the 
survival rate of patients with metastasis is less than 
10%. And as the age increases, the lower the survival 
rate, so the early treatment of patients with rectal 
cancer is of great significance to improve the 
prognosis and survival of patients
14
. In recent years, 
with the advancement of molecular biology 
technology, based on the molecular biology of tumor 
cells, people use cell receptors, key genes and 
regulatory molecules as targets for treatment, so as to 
achieve the purpose of inhibiting tumor growth to 
treatment. At present, the action sites of molecular 
targeted drugs are mainly the traditional signaling 
pathways related to vascular endothelial growth factor 
and epidermal growth factor receptor, which will 




Anlotinib hydrochloride is a multi-targeted 
receptor tyrosine kinase inhibitor, which has been 
approved for the third-line treatment of advanced non-
small cell lung cancer, which can prolong the survival 
of patients and improve clinical symptoms. Vascular 
endothelial cell growth factor and platelet-derived 
growth factor receptor thereby, blocking the signal 
transmission between epidermal factors and inhibiting 
the progression of tumor cells
16
. The signaling 
pathway mediated by c-Kit plays an important role in 
the occurrence, development and metastasis of 
various malignant tumors. Anlotinib can inhibit the 
downstream signaling pathway mediated by the stem 
cell factor receptor, thereby inhibiting tumor growth, 
interfering with multiple biological processes of 
tumor cells
17
. In addition, anlotinib significantly 
inhibits fibroblast growth factor and its receptors and 
other signaling pathways, thereby inhibiting tumor 
angiogenesis, the proliferation and spread of tumors 
play an antagonistic role
18
. Animal experiments have 
found that anlotinib hydrochloride can effectively 
inhibit the growth of transplanted tumors and reduce 
the number of microvessels in the tumor
19
. Anlotinib 
is commonly used in the treatment of lung cancer in 
clinic. Some scholars found that the lung tumor of 
patients with advanced sarcomatoid carcinoma 
showed obvious necrosis and cavity formation after 
two cycles of treatment, and the rest of the lesions did 
not increase significantly, and the condition was 
stable
20
. Some scholars have used anlotinib in patients 
with advanced metastatic colorectal cancer, and found 
that 26 patients had a disease control rate of 75% after 
a course of treatment, and the patient's overall 
treatment was well tolerated
17
. Oralinib hydrochloride 
can avoid serious toxic and side effects such as nausea 
and vomiting caused by traditional chemotherapy, and 
do not require intravenous injection. It is simple and 
convenient to use, and relatively few auxiliary drugs 
provide another treatment for patients who cannot 
receive chemotherapy method. 
The results of this study showed that the total 
effective rate, disease control rate, and one year 
survival rate of the observation group afteranlotinib 
hydrochloride treatment were significantly higher 
than the control group. The tumor progression time 
and survival period were also significantly longer than 
the control group (P <0.05). These findings 
demonstrate use of anlotinib in the treatment of 
patients with advanced colorectal cancer with 
improved clinical efficacy and prolonged survival of 
the patients. In addition, in this study, Kaplan-Meier 
method analysis found that age, treatment plan, lymph 
node metastasis, and residual tumor diameter are all 
risk factors that affect the prognosis of colorectal 
cancer patients (P <0.05). As the age increases, the 
patient’s immune system declines, and cancer cells 
are more prone to metastasis; the smaller the residual 
tumor diameter after surgery, the longer the patient’s 
survival time. It can be seen that complete surgical 
resection of the tumor can help prolong the survival 
time of the patient and improve the prognosis. 
 
Conclusion 
The findings of this study indicates that application 
of anlotinib in patients with advanced colorectal 
cancer for improves clinical efficacy, prolong patient 
survival and quality of life. It is also observed that 
factors such as prognosis and age, treatment plan, 
lymph node metastasis, residual tumor diameter and 
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